CAMELLIA: Phase I dose escalation trial of IMP in acute myeloid leukaemia
This multicentre, non-randomised trial will test the safe dose of an antibody for use in patients with acute myeloid leukaemia. CAMELLIA is currently being set up and is run by OCTRU.
CHOP-OR: Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone With Ofatumumab in Patients With Richter's Syndrome
Richter's syndrome is a non-Hodgkin lymphoma that develops from chronic lymphocytic leukemia. CHOP-OR is a single-arm multicentre non-randomised Phase II trial. It tests whether adding a next-generation monoclonal antibody, Ofatumumab, to a standard chemotherapy protocol will improve the prognosis of patients newly diagnosed with Richter's syndrome. CHOP-OR is run by OCTO. It is closed to recruitment and is in follow-up.
IntReALL HR: International study for treatment of high risk childhood relapsed ALL 2010
IntReALL is a multicentre phase III randomised controlled trial comparing two established protocols for treating relapsed acute lymphoblastic leukemia (ALL) in children, with and without the addition of the drug Epratuzumab.